Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Dasatinib-induced pleural effusion: Chylothorax, an option to consider.

Ferreiro L, San-José E, Suárez-Antelo J, Valdés L.

Ann Thorac Med. 2016 Oct-Dec;11(4):289-293.

2.

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.

Keskin D, Sadri S, Eskazan AE.

Drug Des Devel Ther. 2016 Oct 13;10:3355-3361. Review.

3.
4.

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.

Latagliata R, Stagno F, Annunziata M, Abruzzese E, Iurlo A, Guarini A, Fava C, Gozzini A, Bonifacio M, Sorà F, Leonetti Crescenzi S, Bocchia M, Crugnola M, Castagnetti F, Capodanno I, Galimberti S, Feo C, Porrini R, Pregno P, Rizzo M, Antolino A, Mauro E, Sgherza N, Luciano L, Tiribelli M, Russo Rossi A, Trawinska M, Vigneri P, Breccia M, Rosti G, Alimena G.

Neoplasia. 2016 Sep;18(9):536-40. doi: 10.1016/j.neo.2016.07.005.

5.

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G.

Am J Hematol. 2016 Sep;91(9):869-74. doi: 10.1002/ajh.24423.

6.

Second-generation TKIs: which and when?

Saglio G.

Leuk Suppl. 2012 Aug;1(Suppl 2):S40-2. doi: 10.1038/leusup.2012.22.

7.

Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias.

Lipka DB, Wagner MC, Dziadosz M, Fischer T.

Leukemia. 2016 Oct;30(10):2090-2093. doi: 10.1038/leu.2016.127. No abstract available.

8.

Chronic myeloid leukemia: reminiscences and dreams.

Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ.

Haematologica. 2016 May;101(5):541-58. doi: 10.3324/haematol.2015.139337. Review.

9.

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J, Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, Hehlmann R, Clark RE.

Leukemia. 2016 Aug;30(8):1648-71. doi: 10.1038/leu.2016.104. Review.

10.

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.

Schiffer CA, Cortes JE, Hochhaus A, Saglio G, le Coutre P, Porkka K, Mustjoki S, Mohamed H, Shah NP.

Cancer. 2016 May 1;122(9):1398-407. doi: 10.1002/cncr.29933.

11.

A dose-schedule finding design for phase I-II clinical trials.

Guo B, Li Y, Yuan Y.

J R Stat Soc Ser C Appl Stat. 2016 Feb;65(2):259-272.

PMID:
26877554
12.

Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis.

Rochau U, Kluibenschaedl M, Stenehjem D, Kuan-Ling K, Radich J, Oderda G, Brixner D, Siebert U.

Leuk Res Treatment. 2015;2015:982395. doi: 10.1155/2015/982395.

13.
15.

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.

Boissel N, Renneville A, Leguay T, Lefebvre PC, Recher C, Lecerf T, Delabesse E, Berthon C, Blanchet O, Prebet T, Pautas C, Chevallier P, Leprêtre S, Girault S, Bonmati C, Guièze R, Himberlin C, Randriamalala E, Preudhomme C, Jourdan E, Dombret H, Ifrah N.

Haematologica. 2015 Jun;100(6):780-5. doi: 10.3324/haematol.2014.114884.

16.

The role of dasatinib in the management of chronic myeloid leukemia.

Chen R, Chen B.

Drug Des Devel Ther. 2015 Feb 9;9:773-9. doi: 10.2147/DDDT.S80207. Review.

17.

Reversible ventricular arrythmia induced by dasatinib.

Spechbach H, Morel P, Ing Lorenzini K, Besson M, Gétaz L, Sunthorn H, Chalandon Y.

Clin Case Rep. 2013 Oct;1(1):20-5. doi: 10.1002/ccr3.5.

18.

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.

Brümmendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillié L, Pavlov D, Gogat K, Countouriotis AM, Gambacorti-Passerini C.

Br J Haematol. 2015 Jan;168(1):69-81. doi: 10.1111/bjh.13108.

19.

Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.

Grothey A, George S, van Cutsem E, Blay JY, Sobrero A, Demetri GD.

Oncologist. 2014 Jun;19(6):669-80. doi: 10.1634/theoncologist.2013-0059.

20.

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.

Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S, Durrant S, Kantarjian HM, Khoury HJ, Zaritskey A, Shen ZX, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V, Cortes JE.

Am J Hematol. 2014 Jul;89(7):732-42. doi: 10.1002/ajh.23728.

Items per page

Supplemental Content

Support Center